Author | Conference | Journal | Organization | Year | DOI
Look for results that meet for the following criteria:
Academic
Publications
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

Edit
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study   (Citations: 3)
BibTex | RIS | RefWorks Download
Hedy L Kindler, Tatsuya Ioka, Dirk J Richel, Jaafar Bennouna, Richard Létourneau, Takuji Okusaka, Akihiro Funakoshi, Junji Furuse, Young Suk Park, Shinichi Ohkawa, Gregory M Springett, Harpreet S Wasanhttp://academic.research.microsoft.com/io.ashx?type=5&id=49598089&selfId1=0&selfId2=0&maxNumber=12&query=
Journal: Lancet Oncology - LANCET ONCOL , vol. 12, no. 3, pp. 256-262, 2011
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
    • ...A definitive phase III trial failed to demonstrate an improvement in OS, emphasizing the high attrition in phase III development for this difficult-to-treat disease [31]...
    • ...Of note, this phase III trial ratified the findings of this phase IB study: the addition of axitinib to gemcitabine resulted in acceptable tolerability, with a similar incidence of grade ≥ 3A Es in both arms [31]...

    Jean-Philippe Spano, et al. Phase I study of axitinib (AG013736) in combination with gemcitabine i...

Sort by:

Citations (3)

Share this on